Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Citi has reiterated a Buy rating and $12.00 price target on Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX), representing ~56% upside from the current price of $7.68, following a key opinion leader event at ENDO 2025. According to InvestingPro data, AMLX has demonstrated remarkable momentum with a 255% return over the past year.
The KOL event, held Sunday evening, focused on post-bariatric hypoglycemia (PBH) and presented data on avexitide, Amylyx’s GLP-1 receptor antagonist, highlighting the burden of PBH and limitations of current management approaches. The company, with a market capitalization of $685 million, maintains a "GOOD" overall financial health score on InvestingPro.
Exploratory analyses from avexitide’s phase 2 and phase 2b studies showed that doses of 30mg BID, 60mg QD, and 90mg QD demonstrated reductions in composite level 2 and 3 hypoglycemia events of 40%, 55%, and 64%, respectively.
The new composite analyses provide early insight into how the 90mg SC QD dose may perform in avexitide’s phase 3 LUCIDITY trial, which will use a composite primary endpoint with data expected in the first half of 2026.
Based on the data and composite analyses presented, along with the powering for the phase 3 LUCIDITY trial, Citi believes avexitide is well positioned to demonstrate success. With the next earnings report due on August 7, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research report.
In other recent news, Amylyx Pharmaceuticals Inc. has seen several significant developments. The company announced that the U.S. Food and Drug Administration granted Fast Track designation to its investigational drug AMX0114, aimed at treating amyotrophic lateral sclerosis (ALS). This designation is intended to expedite the development and review process for therapies addressing serious conditions. Additionally, Goldman Sachs resumed coverage of Amylyx with a Buy rating, citing the potential of avexitide, a treatment for post-bariatric surgery hypoglycemia, which could generate significant sales in the U.S. alone.
Citi also initiated coverage with a Buy rating, highlighting Amylyx’s diverse pipeline, including AMX0035 and AMX0114, and emphasizing the company’s strong intellectual property protection. H.C. Wainwright reiterated its Buy rating, focusing on the upcoming LUCIDITY trial data for AMX0114 in ALS. The firm noted the importance of neurofilament light chain levels as a biomarker for ALS treatments. Lastly, TD Cowen started coverage with a Buy rating, expressing optimism about avexitide’s potential market uptake and the prospects of other pipeline candidates. These recent developments underscore Amylyx’s ongoing efforts to advance its pipeline and address unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.